Clearmind Receives Patent for Molecule That May Reduce Desire for Alcohol

Dow Jones08-22

By Connor Hart

Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of a psychedelic molecule.

The Vancouver clinical-stage psychedelic pharmaceutical biotech company said Wednesday its novel psychoactive molecule -- an amine aminoindane, including 5-methoxy-2-aminoindan, or MEAI -- reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience.

The molecule is intended to treat alcohol use disorder and assist in weight loss. It may also be effective in treating binge drinking, the company said.

The patent, granted by the U.S. Patent and Trademark Office, is the company's 29th across 19 patent families.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 21, 2024 18:10 ET (22:10 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2461580472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-22 06:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461580472","market":"sg","top_or_hot":-1,"title":"Clearmind Receives Patent for Molecule That May Reduce Desire for Alcohol","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of a psychedelic molecule. \n</p>\n<p>\n  The Vancouver clinical-stage psychedelic pharmaceutical biotech company said Wednesday its novel psychoactive molecule -- an amine aminoindane, including 5-methoxy-2-aminoindan, or MEAI -- reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience. \n</p>\n<p>\n  The molecule is intended to treat alcohol use disorder and assist in weight loss. It may also be effective in treating binge drinking, the company said. \n</p>\n<p>\n  The patent, granted by the U.S. Patent and Trademark Office, is the company's 29th across 19 patent families. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 21, 2024 18:10 ET (22:10 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Receives Patent for Molecule That May Reduce Desire for Alcohol</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Receives Patent for Molecule That May Reduce Desire for Alcohol\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\n  Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMND","symbol_name":"Clearmind Medicine, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2461580472","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461580472","pubTimestamp":1724278200,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of a psychedelic molecule.The Vancouver clinical-stage psychedelic pharmaceutical biotech company said Wednesday its novel psychoactive molecule -- an amine aminoindane, including 5-methoxy-2-aminoindan, or MEAI -- reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience.The molecule is intended to treat alcohol use disorder and assist in weight loss. It may also be effective in treating binge drinking, the company said.The patent, granted by the U.S. Patent and Trademark Office, is the company's 29th across 19 patent families.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMND":"Clearmind Medicine, Inc.","BK4007":"制药"},"translate_title":"Clearmind获得可减少饮酒欲望的分子专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Clearmind Medicine received approval for a new patent that claims a method of regulating the consumption of alcoholic beverages and controlling binge behavior through the administration of a psychedelic molecule. \n\n\n  The Vancouver clinical-stage psychedelic pharmaceutical biotech company said Wednesday its novel psychoactive molecule -- an amine aminoindane, including 5-methoxy-2-aminoindan, or MEAI -- reduces the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience. \n\n\n  The molecule is intended to treat alcohol use disorder and assist in weight loss. It may also be effective in treating binge drinking, the company said. \n\n\n  The patent, granted by the U.S. Patent and Trademark Office, is the company's 29th across 19 patent families. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2024 18:10 ET (22:10 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461580472"}